Supplementary Table 1 and 2 from Potential Role of mTORC2 as a Therapeutic Target in Clear Cell Carcinoma of the Ovary
Takeshi Hisamatsu(The University of Osaka), Tadashi Kimura(Sakai Municipal Hospital), Tomoyuki Sasano(Yamagata University), Russell J. Schilder, Seiji Mabuchi(The University of Osaka), Kimihiko Ito, Kenjiro Sawada(Gynecologic Oncology Group), Ryoko Takahashi(The University of Tokyo), Mahiru Kawano(Yamagata University), Hirohisa Kurachi(Osaka Women's and Children's Hospital), Yuri Matsumoto(Yamagata University), Joseph R. Testa(Fox Chase Cancer Center)
Cited by 0
Related Papers
Integrated genomic analyses of ovarian carcinoma
|Nature|2011|8.2k
Genetic Dissection of the Oncogenic mTOR Pathway Reveals Druggable Addiction to Translational Control via 4EBP-eIF4E
|Cancer Cell|2010|463
Estrogen Induces the Akt-dependent Activation of Endothelial Nitric-oxide Synthase in Vascular Endothelial Cells
|Journal of Biological Chemistry|2001|387
High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas.
|Proceedings of the National Academy of Sciences|1995|365